Data / Drug companies / Atomoxetine hydrochloride
Atomoxetine hydrochloride: 8 companies and 28 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Atomoxetine hydrochloride is listed in the FDA National Drug Code Directory by 8 companies, with 28 products in commercial distribution. 19 of the products (67.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; solution, and the newest product started marketing on March 20, 2026.
The request: Get every company that lists atomoxetine hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 8
- Products
- 28
- Generic (ANDA) products
- 19 (67.9%)
- Application numbers
- 3
- Routes
- Oral
- Brand names
- Strattera, Atoncy
- openFDA record search
- api.fda.gov
Companies that list atomoxetine hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Apotex Corp. | 7 | capsule | Generic drugs (ANDA) | May 21, 2018 |
| Eli Lilly and Company | 7 | capsule | New drug applications (NDA) | February 14, 2005 |
| Golden State Medical Supply, Inc. | 7 | capsule | Generic drugs (ANDA) | May 30, 2017 |
| AvPAK | 3 | capsule | Generic drugs (ANDA) | July 7, 2020 |
| A-S Medication Solutions | 1 | capsule | Generic drugs (ANDA) | May 21, 2018 |
| Advagen Pharma Ltd | 1 | solution | Authorized generics (NDA) | March 20, 2026 |
| Remedyrepack Inc. | 1 | capsule | Generic drugs (ANDA) | March 19, 2025 |
| Validus Pharmaceuticals LLC | 1 | solution | New drug applications (NDA) | March 20, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 26 | 92.9% |
| Solution | 2 | 7.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 67.9% |
| New drug applications (NDA) | 8 | 28.6% |
| Authorized generics (NDA) | 1 | 3.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Norepinephrine Reuptake Inhibitor | 28 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.